Wegovy vs Retatrutide Side-Effect Profile Head-to-Head

What Are Wegovy and Retatrutide, and Why Does Mechanism Matter for Side Effects?

The mechanism a drug uses to produce weight loss directly predicts which side effects appear, how severe they are, and when during titration they peak. Wegovy is a once-weekly subcutaneous injection of semaglutide 2.4 mg, a GLP-1 receptor agonist. Retatrutide is a single molecule that activates three receptors simultaneously: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. That extra receptor activity is why the two drugs produce meaningfully different side-effect patterns even though GI complaints dominate both profiles.

GLP-1 Receptor Activation: The Shared Root of GI Side Effects

GLP-1 receptor agonism slows gastric emptying and reduces appetite through central hypothalamic signaling. That slower gastric emptying is directly responsible for nausea, vomiting, early satiety, and belching. Both Wegovy and retatrutide carry this risk because both activate GLP-1 receptors. The FDA-approved Wegovy prescribing information lists nausea as occurring in 44% of patients at the 2.4 mg maintenance dose versus 16% on placebo.

In STEP-1 (N=1,961), nausea was reported by 44.2% of semaglutide participants compared with 16.0% in the placebo group, and vomiting occurred in 24.5% versus 6.8%, respectively [1]. These events were predominantly mild to moderate and clustered during the dose-escalation phase across weeks 1 through 16.

GIP Receptor Activation: Potential Metabolic Benefits With Unclear GI Contribution

GIP receptor agonism has complex effects on fat tissue and insulin secretion. Animal data suggest GIP co-agonism may actually reduce nausea relative to pure GLP-1 agonism at equivalent weight-loss doses, a hypothesis partly supported by the tirzepatide clinical program. Retatrutide extends this logic further by also activating the glucagon receptor.

Glucagon Receptor Activation: The Wild Card

Glucagon receptor agonism increases hepatic glucose output, raises energy expenditure, and promotes lipolysis. It also relaxes the lower esophageal sphincter in some models, which could worsen reflux symptoms. The net effect in humans is still being characterized in the ongoing Phase 3 program for retatrutide.

Wegovy Side Effects: What the STEP-1 Data Actually Show

STEP-1 enrolled 1,961 adults with a BMI of 30 or above (or 27 with at least one weight-related comorbidity) and produced the most granular safety dataset available for semaglutide 2.4 mg [1].

Gastrointestinal Adverse Events

Nausea (44.2%), diarrhea (29.7%), vomiting (24.5%), and constipation (24.2%) were the four most common adverse events in the semaglutide arm [1]. Serious GI adverse events occurred in 1.6% of semaglutide patients. Gallbladder disease, including cholelithiasis, appeared in 2.6% of the semaglutide group versus 1.2% on placebo, a finding consistent with rapid fat loss increasing bile saturation rather than a direct drug toxicity.

Discontinuation due to GI adverse events happened in 4.5% of semaglutide participants in STEP-1. That number is clinically meaningful: one in 22 patients stopped the drug entirely because of GI tolerability.

Injection-Site and Cardiovascular Events

Injection-site reactions occurred in 1.5% of participants. Heart rate increased by a mean of 1 to 4 beats per minute across the STEP trials, a known class effect of GLP-1 receptor agonists. No increased risk of major adverse cardiovascular events was observed in STEP-1, though that trial was not powered for cardiovascular outcomes. The SELECT trial (N=17,604), published in 2023, subsequently showed a 20% relative risk reduction in major cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity [2].

Thyroid and Pancreatitis Risk

The Wegovy label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies. In STEP-1, calcitonin elevations and thyroid neoplasms were numerically similar between groups, with no statistically significant difference. Pancreatitis occurred in 0.1% of semaglutide patients [1]. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 are contraindicated.

Retatrutide Side Effects: What the Phase 2 Data Show

The Jastreboff et al. Phase 2 trial (NEJM 2023, N=338) randomized adults to placebo or one of five retatrutide dose groups (1 mg, 4 mg, 8 mg, or 12 mg at two different titration rates) for 48 weeks [3]. It is the primary safety dataset available for retatrutide in humans and must be interpreted as Phase 2 data, meaning the sample size and follow-up duration are smaller than what a full Phase 3 program will provide.

GI Adverse Events at Each Dose Level

Nausea, vomiting, and diarrhea increased in a clear dose-dependent manner. At the 12 mg maintenance dose, nausea was reported in approximately 62% of participants, vomiting in approximately 26%, and diarrhea in approximately 41% [3]. Constipation appeared less frequently at higher doses relative to nausea, which differs slightly from the Wegovy pattern where constipation rates approach diarrhea rates.

Discontinuation due to adverse events reached 16% in the 12 mg group, compared with 4.5% in STEP-1 for Wegovy. That gap is likely a combination of genuinely higher GI burden at 12 mg and the faster titration schedule used in some Phase 2 groups. Phase 3 protocols typically use slower titration to improve tolerability.

Hypoglycemia and Blood Pressure

Because retatrutide activates the glucagon receptor, hypoglycemia was an early concern. In the Phase 2 trial, symptomatic hypoglycemia occurred in less than 5% of participants without baseline diabetes, and no severe hypoglycemia episodes requiring assistance were reported in the non-diabetic cohort [3]. Blood pressure fell meaningfully: systolic blood pressure dropped by approximately 6 to 9 mmHg in the higher-dose groups, which is a clinically useful secondary effect.

Heart Rate and Cardiac Safety

Heart rate increased by a mean of 3 to 6 beats per minute across retatrutide dose groups, similar in magnitude to what is seen with semaglutide and tirzepatide [3]. No dedicated cardiovascular outcomes trial for retatrutide has been published. The Phase 3 TRIUMPH program is expected to include a cardiovascular safety cohort, but results are not yet available.

Thyroid, Pancreatitis, and Injection-Site Findings

Retatrutide produced calcitonin elevations in a small number of participants. As a GLP-1 receptor agonist, it carries the same theoretical thyroid C-cell risk that applies to the entire class. Injection-site reactions occurred in roughly 5 to 7% of participants at higher doses, somewhat above the Wegovy rate, possibly related to the formulation pH at those concentrations. Amylase and lipase elevations were observed in a minority of participants, though no clinical pancreatitis cases were confirmed in the published Phase 2 data [3].

Direct Side-Effect Comparison: A Structured Framework

No published randomized head-to-head safety trial compares Wegovy and retatrutide directly. The following comparison draws on the STEP-1 and Jastreboff Phase 2 datasets using consistent outcome categories. Readers should note that the trials differed in duration (68 vs. 48 weeks), population size (1,961 vs. 338), and titration schedule, all of which affect adverse-event rates independently of the drugs themselves.

Nausea

Wegovy: 44.2% (STEP-1, 68 weeks, mature titration protocol) [1]. Retatrutide 12 mg: approximately 62% (Phase 2, 48 weeks, faster titration in some arms) [3]. The difference of roughly 18 percentage points likely reflects both the additional glucagon receptor component and the steeper titration used in the Phase 2 design. Whether Phase 3 protocols with slower up-titration will narrow this gap is a key unanswered question.

Vomiting

Wegovy: 24.5% [1]. Retatrutide 12 mg: approximately 26% [3]. These are within a few percentage points of each other, suggesting the incremental receptor activity does not substantially worsen vomiting beyond what GLP-1 agonism alone produces.

Diarrhea

Wegovy: 29.7% [1]. Retatrutide 12 mg: approximately 41% [3]. The higher diarrhea rate with retatrutide may relate to the glucagon receptor's effect on intestinal motility, though this is mechanistically unconfirmed in humans.

Constipation

Wegovy: 24.2% [1]. Retatrutide 12 mg: lower relative to other GI symptoms in Phase 2 reports [3]. The divergence here is one of the more clinically interesting differences between the profiles.

Discontinuation Due to Adverse Events

Wegovy: 4.5% due to GI events in STEP-1 [1]. Retatrutide 12 mg: 16% due to adverse events in Phase 2 [3]. This is the starkest numerical difference between the two drugs in current data, though it is almost certainly influenced by trial design.

Serious Adverse Events

Wegovy: 9.8% of semaglutide patients vs. 6.4% placebo in STEP-1 [1]. Retatrutide Phase 2: serious adverse events were reported but the absolute rate at 12 mg was not materially higher than placebo in the published summary [3]. Phase 2 trials are underpowered to detect rare serious events.

Efficacy Context: Why Tolerating More Side Effects Might Be Justified

Side effects only matter clinically relative to benefits. Retatrutide's Phase 2 results produced 24.2% mean body-weight loss at 48 weeks with the 12 mg dose, compared with 14.9% at 68 weeks for Wegovy in STEP-1 [1, 3]. The authors of the Jastreboff Phase 2 paper noted that "the magnitude of weight reduction observed with retatrutide was greater than that reported for other antiobesity medications in trials of similar duration" [3].

Putting the Numbers in Clinical Terms

A patient weighing 120 kg (264 lb) at baseline would lose approximately 17.9 kg (39 lb) on Wegovy over 68 weeks. The same patient on retatrutide 12 mg would project to lose approximately 29 kg (64 lb) over 48 weeks based on the Phase 2 means. That 25 kg difference in projected loss is large enough to push some patients past thresholds for bariatric surgery eligibility criteria or joint replacement candidacy.

Weight Loss Does Not Equal Metabolic Equivalence

Faster, larger fat mass reduction carries its own risks: gallstone formation rates increase with rapid weight loss, and lean mass preservation depends heavily on protein intake and resistance training during the loss phase. Neither trial was designed to compare body composition changes between the two agents.

Who Is Currently a Candidate for Each Drug?

Wegovy: The Current Standard of Care

Wegovy holds FDA approval for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The SELECT cardiovascular outcome data [2] support its use in patients with established atherosclerotic cardiovascular disease. A pediatric indication for adolescents aged 12 and older was approved in December 2022.

Prescribers at HealthRX currently use Wegovy as first-line injectable therapy for chronic weight management in patients without contraindications, consistent with the Endocrine Society 2023 Clinical Practice Guideline on Pharmacological Management of Obesity.

Retatrutide: Phase 3 and Access Through Trials

Retatrutide is not FDA-approved. Access is currently limited to enrollment in the Phase 3 TRIUMPH clinical trial program or through investigational use. Patients asking their clinician about retatrutide should be counseled that efficacy data comes from a single Phase 2 trial with 338 participants and 48 weeks of follow-up. Phase 3 data, when published, will provide the sample sizes and duration needed to characterize rare adverse events and long-term cardiovascular outcomes.

Titration Strategy and Managing GI Side Effects for Both Drugs

Slower dose escalation is the single most effective strategy for reducing GI adverse events with either agent. For Wegovy, the approved titration schedule starts at 0.25 mg weekly for 4 weeks, stepping through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose at week 16.

Practical Tolerability Tips That Apply to Both Drugs

Small, low-fat meals reduce gastric distension and slow gastric-emptying symptoms. Eating slowly and stopping before full satiety helps. Ginger supplementation at 1 to 2 g daily has modest evidence for reducing GLP-1-class nausea. Ondansetron 4 mg as needed is used off-label by some clinicians for breakthrough nausea during titration.

Dose pauses, rather than dose reductions, are preferred for transient GI flares. The Wegovy prescribing information allows a 4-week dose pause before resuming titration at the last tolerated dose.

If Phase 3 data show that retatrutide's GI burden is substantially lower than Phase 2 data suggest, perhaps due to optimized titration, it will change the tolerability calculus significantly. Phase 2 titration schedules are rarely the final approved protocol.

Emerging Safety Signals: What to Watch in Phase 3

Lean mass loss is a concern with any obesity pharmacotherapy that produces rapid weight loss. Early body composition data from tirzepatide trials showed proportional lean and fat mass loss, but retatrutide's glucagon component may affect protein catabolism differently. Phase 3 protocols for TRIUMPH include DEXA-based body composition endpoints.

Bone density is another signal worth monitoring. Rapid weight loss is associated with reduced bone mineral density, particularly at the hip [4]. Neither Wegovy nor retatrutide Phase 2 data showed fracture signals, but longer follow-up is needed.

Psychiatric adverse events received post-marketing attention for the GLP-1 class in 2023 after case reports of suicidal ideation. The FDA's 2023 safety review did not establish causality and noted the difficulty of separating drug effects from the high background rate of depression in patients with obesity. Clinicians prescribing either agent should screen for depression at baseline and monitor during treatment.

Can You Switch from Wegovy to Retatrutide?

Retatrutide is not currently available outside clinical trials, so a formal switch protocol does not exist. Theoretically, a switch would involve stopping semaglutide and initiating retatrutide at its lowest starting dose after a washout period of at least five half-lives. Semaglutide's half-life is approximately 7 days, placing the practical washout at 4 to 5 weeks.

Adding any new GLP-1-containing agent shortly after stopping another increases the risk of additive GI adverse events during the early titration period. If retatrutide receives FDA approval and a switch becomes clinically relevant, HealthRX will publish specific protocol guidance based on the approved prescribing information.

Is Wegovy Better Than Retatrutide?

The question depends entirely on the outcome being prioritized. For side-effect tolerability with current data, Wegovy has the lower GI burden (44% nausea vs. Approximately 62% for retatrutide 12 mg) and the lower discontinuation rate (4.5% vs. 16%). For absolute weight loss, retatrutide 12 mg produces substantially more loss (24.2% vs. 14.9%) over a shorter timeframe. For regulatory certainty and cardiovascular outcome evidence, Wegovy wins by default because it has 4 years of post-marketing data, a cardiovascular outcomes trial (SELECT), and FDA approval.

Retatrutide has the potential to become the most effective non-surgical obesity treatment yet studied. Whether its Phase 2 side-effect profile holds in the larger, slower-titration Phase 3 population will be the central question determining real-world adoption.

The Obesity Society's position statement on pharmacotherapy makes clear that drug selection should be individualized based on comorbidities, tolerability history, cost, and patient preference. No single agent is universally superior.